Market Place
Sourcing Support
Xenon to Present at Upcoming Investor Conferences
13 Nov 2024 //
GLOBENEWSWIRE
Xenon to Report Q3 2024 Financial Results on Nov 12, 2024
05 Nov 2024 //
GLOBENEWSWIRE
Xenon Showcases Azetukalner Data at European Epilepsy Congress
09 Sep 2024 //
GLOBENEWSWIRE
Xenon Appoints Matthew Ronsheim As Chief Operating Officer
12 Aug 2024 //
GLOBENEWSWIRE
Xenon to Report Q2 2024 Financial Results on August 8, 2024
01 Aug 2024 //
GLOBENEWSWIRE
Xenon Pharma: Presenting At Goldman Sachs Healthcare Conference
05 Jun 2024 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Xenon Pharma at RBC Healthcare Conference 2024
06 May 2024 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at Bloom Burton & Co. Conference
10 Apr 2024 //
GLOBENEWSWIRE
Xenon Pharma Announces Closing of $345.0 Million Upsized Public Offering
04 Dec 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs
02 Dec 2023 //
GLOBENEWSWIRE
Xenon offers $300M in shares after touting path ahead for MDD program
30 Nov 2023 //
ENDPTS
Xenon Pharmaceuticals Announces Proposed Public Offering
29 Nov 2023 //
GLOBENEWSWIRE
Xenon Pharma Announces Pricing of Upsized $300.0 Million Public Offering
29 Nov 2023 //
GLOBENEWSWIRE
Xenon`s MDD med fails ph. 2, elevating seizure potential
28 Nov 2023 //
FIERCE BIOTECH
Xenon Announces Topline Results from Phase 2 X-NOVA Trial of XEN1101
27 Nov 2023 //
GLOBENEWSWIRE
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
11 Nov 2023 //
BIOSPACE
Double whammy for Neurocrine as Takeda, Xenon pacts fail
10 Nov 2023 //
FIERCE BIOTECH
Xenon Pharma Provides Update on Partnered Program with Neurocrine Biosciences
09 Nov 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Xenon Announces Conference to Discuss Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Xenon Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
04 Sep 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Appointed Gillian M. Cannon and Justin Gover
08 Aug 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Xenon to Present at the 2023 RBC Capital Markets Global Healthcare Conference
11 May 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Xenon Showcases Its XEN1101 Epilepsy Program at the 2023 AAN Annual Meeting
24 Apr 2023 //
GLOBENEWSWIRE
Xenon to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
21 Apr 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
22 Mar 2023 //
GLOBENEWSWIRE
Xenon Pharma to Discuss Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
GLOBENEWSWIRE
Xenon Pharma to Present at the SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
09 Jan 2023 //
GLOBENEWSWIRE
Xenon Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Xenon Pharma to Present at the Bank of America Securities Biotech SMID
30 Nov 2022 //
GLOBENEWSWIRE
Xenon Reports3Q 2022 Financial Results and Provides Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Xenon Pharma Strengthens Leadership Team with Appointment of Andrea DiFabio
07 Nov 2022 //
GLOBENEWSWIRE
Xenon Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2
03 Nov 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss 3Q 2022
01 Nov 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
01 Sep 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Xenon Pharma to Present at 13th Annual Wedbush PacGrow Healthcare Conference
08 Aug 2022 //
GLOBENEWSWIRE
Xenon Pharma to Discuss Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
Xenon Pharma to Present at the William Blair Biotech Focus Conference 2022
11 Jul 2022 //
GLOBENEWSWIRE
Xenon Closes $287.5M Public Offering with Full Exercise of Underwriters Option
27 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharma Provides Update on Additional Positive Data from XEN1101 Program
22 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Announces Proposed Public Offering
22 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering
22 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharma Announces Positive Outcome of End-of-PII Meeting with the FDA
21 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Xenon Pharma Initiates PII Trial to Evaluate XEN1101 in MDD
03 May 2022 //
GLOBENEWSWIRE
Xenon Pharma to Discuss First Quarter 2022 Financial Results
03 May 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
25 Apr 2022 //
GLOBENEWSWIRE
Xenon Pharma to Present at 21st Annual Needham Virtual Healthcare Conference
04 Apr 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days
22 Mar 2022 //
GLOBENEWSWIRE
Xenon Pharma Reports 2021 Financial Results and Provides Corporate Update
01 Mar 2022 //
GLOBENEWSWIRE
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Conference
14 Feb 2022 //
GLOBENEWSWIRE
Xenon Collaborates with Neurocrine Bio, Achieves $15M Regulatory Milestone
12 Jan 2022 //
GLOBENEWSWIRE
Xenon Announces Conference Call and Webcast to Discuss Q3 2021 Financial Results
03 Nov 2021 //
GLOBENEWSWIRE
